PT  - JOURNAL ARTICLE
AU  - Goel, Sunny
AU  - Slomovich, Sharon
AU  - Edris, Sami
AU  - Rubinstein, Gal
AU  - Agarwal, Chirag
AU  - Park, Won Jun
AU  - Zinkovsky, Daniel
AU  - Hooda, Amit
AU  - Melarcode Krishnamoorthy, Parasuram
AU  - Gidwani, Umesh K.
AU  - Sharma, Samin K.
AU  - Kini, Annapoorna
TI  - Fractional flow reserve versus angiography for revascularization in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials
AID  - 10.1101/2023.08.18.23294291
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.18.23294291
4099  - http://medrxiv.org/content/early/2023/08/21/2023.08.18.23294291.short
4100  - http://medrxiv.org/content/early/2023/08/21/2023.08.18.23294291.full
AB  - Background Fractional flow reserve (FFR) is routinely used to assess the ischemic potential of a coronary artery lesion. However, recently published randomized control trials have questioned the advantage of FFR over angiography to guide revascularization. Whether FFR guided revascularization provides clinical benefit over angiography remains unclear.Methods We performed a meta-analysis in patients with stable coronary artery disease (CAD), acute coronary syndrome (ACS), multivessel or single vessel CAD undergoing revascularization comparing FFR versus angiography to guide revascularization. Randomized control trials comparing FFR versus angiography guided revascularization were searched through PubMed, Cumulative Index to Nursing and Allied Health Literature, Cochrane Central, Scopus, Google Scholar, and Web of Science databases. The primary endpoints included cardiovascular mortality, repeat revascularization, myocardial infarction, major adverse cardiac events, stroke or transient ischemic attack and target lesion revascularization. We also evaluated the procedural outcomes including the average number of stents used between the two groups, procedure time and contrast volume used. Event rates were compared using a forest plot of odds ratios using a random-effects model assuming interstudy heterogeneity.Results The meta-analysis included 13 trials in which 7415 patients met the eligibility criteria. There was no significant difference between the FFR versus angiography guided revascularization groups across all clinical measures including all-cause mortality (OR = 1.06, 95% CI = 0.74-1.53, P = 0.74, I2= 27%), cardiovascular mortality (OR = 0.81, 95% CI = 0.43-1.52, P = 0.51, I2= 44%), repeat revascularization (OR = 1.02, 95% CI = 0.83-1.26, P = 0.83, I2= 17%), myocardial infarction (OR = 0.92, 95% CI = 0.69-1.21, P = 0.54, I2= 36%), major adverse cardiac event (OR = 0.82, 95% CI = 0.62-1.08, P = 0.15, I2= 41%), stroke or transient ischemic attack (OR = 1.49, 95% CI = 0.87-2.55, P = 0.15, I2= 0%) and target lesion revascularization (OR = 0.86, 95% CI = 0.44-1.69, P = 0.67, I2= 0%). A sensitivity analysis was performed for studies that included patients exclusively with an ACS and studies that used FFR coronary artery bypass grafting (CABG) as a revascularization strategy. There was no difference in any of the clinical outcomes between the two groups in the sensitivity analysis. In terms of procedural outcomes, the average number of stents used was lower in the FFR group as compared to the angiography group, mean difference (MD) of −0.79 (95% CI = − 1.10, − 0.48), P < 0.00001) with no difference in procedure time or contrast volume used.Conclusion This meta-analysis suggests that FFR when used in conjunction with angiography prevents unnecessary PCI without any difference in clinical outcomes between the two groups.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementNo external funding was received for any aspect of the submitted manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author upon reasonable request.